Abstract Body

Increasing the period in which HIV recency assays can identify recent infection without increasing misclassification of specimens as recent will allow studies to use smaller sample sizes.  We describe an HIV avidity assay that identifies recent HIV infection by detection of low avidity antibodies along with detection of HIV p24 Ag in anti-HIV negative specimens thus extending the duration that recent HIV infection can be determined.

Specimens were tested for using the BioPlex 2200 HIV Ag-Ab assay.  This ‘5th generation’ assay allows separate detection and identification of anti-HIV 1, anti-HIV-2 and HIV p24 Ag unlike 4th generation which give a single signal.  An antibody avidity modification using 1M guanidine allowed determination of an avidity index.  Presence of p24 Ag was determined on each sample and a subset of specimens diluted with Guanidine and PBS. Results were compared with an existing HIV incidence assay (HIV Limiting Antigen).   150 specimens were tested comprising HIV seroconversion panels, known anti-HIV positive specimens and acute p24 Ag only positive specimens were used.

Antibody avidity increased over time.  Where p24 Ag was detected prior to seroconversion addition of guanidine and/or dilution of specimen had only a minimal effect on level of p24 detection but it remained detectable. Using a cut-off of <80% AI for recent infection concordance with LAg assay result was over 90%.  Of four mismatched specimens two were close to the recency cut-off for either LAg or BioPlex avidity.

This assay has a sensitive and specific HIV diagnostic capability and potential to allow HIV recency discrimination on the same platform. Initial results show a comparable performance to the market leading incidence assay in those anti-HIV positive.  However, the ability to identify Ab negative/Ag positive specimens increases the duration in which ‘true’ recent infection can be determined. This increases duration of detectable recent infection by up to two weeks but importantly identifies ‘true’ recent infections that may otherwise be discarded.   Our data demonstrate that assays containing an antigen detection component are compatible with use in HIV incidence methodologies.  The potential of this assay to be able to provide specific diagnostic differentiation of HIV-1 from HIV-2 and p24 Ag with modification to allow identification of recent HIV infection may change HIV diagnostic algorithms to allow the incorporation of recency testing into routine practice.